Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 201–300 of 1,001
Matteau, A., Yeh, R. W., Camenzind, E., Steg, P. G., Wijns, W. C., Mills, J. D., Gershlick, A., de Belder, M., Ducrocq, G., & Mauri, L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.05.036 · Cited by 71
Self-citationAntithrombotic Therapy for Peripheral Artery Disease
Hussain, M. A., Al-Omran, M., Creager, M. A., Anand, S. S., Verma, S., & Bhatt, D. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.483 · Cited by 69
Yamashita, Y., Shiomi, H., Morimoto, T., Yaku, H., Furukawa, Y., Nakagawa, Y., Andò, K., Kadota, K., Abe, M., Nagao, K., et al. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002790 · Cited by 69
Palmerini, T., & Stone, G. W. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv712 · Cited by 70
“Consistent with this hypothesis are data from the large-scale, prospective, multicenter ADAPT-DES registry in which platelet reactivity after aspirin and clopidogrel loading were assessed with the VerifyNow point of care assay in 8665 patients receiving DES.38 In this study, high platelet reactivity on clopidogrel but…”
BackgroundInfluentialPre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?
Sibbing, D., Kastrati, A., & Berger, P. B. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv717 · Cited by 76
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Bhatt, D. L., Pollack, C. V., Mazer, C. D., Angiolillo, D. J., Steg, P. G., James, S. K., Weitz, J. I., Ramnath, R., Arnold, S. E., Mays, M. C., et al. (2021) · NEJM Evidence · doi:10.1056/evidoa2100047 · Cited by 67
Self-citationAntithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Valgimigli, M., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Halvorsen, S., James, S. K., Jüni, P., Kunadian, V., Landi, A., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad032 · Cited by 67
The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence
Leader, A., Zelikson-Saporta, R., Pereg, D., Spectre, G., Rozovski, U., Raanani, P., Hermoni, D., & Lishner, M. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.022 · Cited by 71
Cavender, M. A., White, W. B., Jarolím, P., Bakris, G. L., Cushman, W. C., Kupfer, S., Gao, Q., Mehta, C. R., Zannad, F. M., Cannon, C. P., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024632 · Cited by 70
Bainey, K. R., Welsh, R. C., Connolly, S. J., Marsden, T., Bosch, J., Fox, K. A. A., Steg, P. G., Vinereanu, D., Connolly, D. L., Berkowitz, S. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044598 · Cited by 62
Self-citationMoving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling
Pencina, M. J., & Peterson, E. D. (2016) · JAMA · doi:10.1001/jama.2016.4839 · Cited by 66
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Acute, periprocedural and longterm antithrombotic therapy in older adults
Andreotti, F., Geisler, T., Collet, J., Gigante, B., Gorog, D. A., Halvorsen, S., Lip, G. Y. H., Morais, J., Navarese, E. P., Patrono, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac515 · Cited by 70
Trends in acute myocardial infarction mortality in the European Union, 2012–2020
Zuin, M., Rigatelli, G., Temporelli, P. L., Fusco, S. A. D., Colivicchi, F., Pasquetto, G., & Bilato, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad214 · Cited by 65
Lee, S., Hong, M., Palmerini, T., Kim, H.-S., Valgimigli, M., Feres, F., Colombo, A., Gilard, M., Shin, D., Kim, J., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.10.015 · Cited by 64
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Clinical Updates in Coronary Artery Disease: A Comprehensive Review
Bottardi, A., Prado, G. F. A., Lunardi, M., Fezzi, S., Pesarini, G., Tavella, D., Scarsini, R., & Ribichini, F. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164600 · Cited by 68
“On the contrary, in patients at high ischemic risk and without increased risk of major bleeding, DAPT can be extended (>12 months) [155,156] (Figure 3).”
BackgroundPark, T. K., Song, Y. B., Ahn, J., Carriere, K. C., Hahn, J., Yang, J. H., Choi, S., Choi, J., Lee, S. H., & Gwon, H. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.002816 · Cited by 65
Gragnano, F., Heg, D., Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Branca, M., Serruys, P. W. J. C., Benit, E., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa106 · Cited by 64
Self-citationKotecha, T., & Rakhit, R. D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s43 · Cited by 72
Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema
Gjorup, C. A., Grøenvold, M., Hendel, H. W., Dahlstrøm, K., Drzewiecki, K. T., Klausen, T. W., & Hölmich, L. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.052 · Cited by 62
Pasalic, L., Wing‐Lun, E., Lau, J. K., Campbell, H., Pennings, G. J., Lau, E., Connor, D., Liang, H., Muller, D. W., Kritharides, L., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14008 · Cited by 65
D’Ascenzo, F., Moretti, C., Bianco, M., Bernardi, A., Taha, S., Cerrato, E., Omedè, P., Montefusco, A., Frangieh, A. H., Lee, C. W., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.005 · Cited by 61
Capodanno, D., & Angiolillo, D. J. (2020) · Circulation · doi:10.1161/circulationaha.120.045465 · Cited by 65
Vogel, B., Baber, U., Cohen, D. J., Sartori, S., Sharma, S. K., Angiolillo, D. J., Farhan, S., Goel, R., Zhang, Z., Briguori, C., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1720 · Cited by 61
Self-citationSoden, P. A., Zettervall, S. L., Ultee, K. H. J., Landon, B. E., O'Malley, A. J., Goodney, P. P., DeMartino, R. R., Arya, S., & Schermerhorn, M. L. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.05.098 · Cited by 59
“[10] The benefit to DAPT in this setting is thought to not only be from prevention of stent thrombosis but also from a decrease in atherothrombotic events in coronary vessels outside of the stented artery.[15] This is further supported by evidence that medically managed patients with acute coronary syndrome had fewer…”
ResultDidier, R. J., Morice, M., Barragan, P. T., Noryani, A. A. L., Noor, H. A., Majwal, T., Hovasse, T., Castellant, P., Schneeberger, M., Maillard, L., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.03.049 · Cited by 61
Gargiulo, G., Valgimigli, M., Capodanno, D., & Bittl, J. A. (2017) · EuroIntervention · doi:10.4244/eij-d-17-00468 · Cited by 63
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents
Hermiller, J. B., Krucoff, M. W., Kereiakes, D. J., Windecker, S., Steg, P. G., Yeh, R. W., Cohen, D. J., Cutlip, D. E., Massaro, J. M., Hsieh, W.-H., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.10.001 · Cited by 60
“The primary study analysis within all randomized DES-treated patients compared randomized treatments with respect to the primary effectiveness end points of stent thrombosis and MACCE from 12 to 30 months post-procedure, and the primary safety endpoint of moderate or severe bleeding from 12 to 30 months post-procedure…”
BackgroundMethodResultSelf-citationPiccolo, R., Gargiulo, G., Franzone, A., Santucci, A., Ariotti, S., Baldo, A., Tumscitz, C., Moschovitis, A., Windecker, S., & Valgimigli, M. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2389 · Cited by 66
Platelet-targeted pharmacologic treatments as anti-cancer therapy
Gresele, P., Momi, S., Malvestiti, M., & Sebastiano, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9679-8 · Cited by 61
Benenati, S., Galli, M., Marzo, V. D., Pescetelli, F., Toma, M., Andreotti, F., Bona, R. D., Canepa, M., Ameri, P., Crea, F., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa001 · Cited by 63
Kereiakes, D. J., Yeh, R. W., Massaro, J. M., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Gershlick, A., Darius, H., Meredith, I. T., Ormiston, J. A., et al. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.05.026 · Cited by 59
“The results comparing continued thienopyridine versus placebo (randomized treatment) in each of the DES- and BMStreated cohorts have been reported separately (9,10).”
BackgroundResultSelf-citationMatsubara, Y., Matsumoto, T., Inoue, K., Matsuda, D., Yoshiga, R., Yoshiya, K., Furuyama, T., & Maehara, Y. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.09.030 · Cited by 60
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
“The DAPT study showed that longer duration of DAPT following PCI results in lower stent thrombosis and recurrent MIs, but higher bleeding and all-cause mortality compared with a 12-month duration [167].”
BackgroundCardoso, R. N., Knijnik, L., Whelton, S. P., Rivera, M., Gluckman, T. J., Metkus, T. S., Blumenthal, R. S., & McEvoy, J. W. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.07.083 · Cited by 59
Dual Antiplatelet Therapy: A Concise Review for Clinicians
Virk, H. U. H., Escobar, J., Rodríguez, M., Bates, E., Khalid, U., Jneid, H. M., Birnbaum, Y., Levine, G. N., Smith, S. C., & Krittanawong, C. (2023) · Life · doi:10.3390/life13071580 · Cited by 63
“Both groups had an increased risk of stent thrombosis and MI after stopping thienopyridine [48].”
BackgroundLi, Y., Li, J., Wang, B., Jing, Q., Zeng, Y., Hou, A., Wang, Z., Liu, A., Zhang, J., Zhang, Y., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0534 · Cited by 59
Giacoppo, D., Gragnano, F., Watanabe, H., Kimura, T., Kang, J., Park, K. W., Kim, H.-S., Pettersen, A. R., Bhatt, D. L., Pocock, S., et al. (2025) · BMJ · doi:10.1136/bmj-2024-082561 · Cited by 59
Feres, F., Ra, C., Siqueira, D., Costa, J., Jr., Chamié, D., Staico, R., Aj, C., Abizaid, A., Marin‐Neto, J. A., Rassi, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170111 · Cited by 58
Update on Antithrombotic Therapy after Percutaneous Coronary Intervention
Saito, Y., & Kobayashi, Y. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3685-19 · Cited by 57
“05) were higher in the continued DAPT group than in the other group (11).”
BackgroundMethodTan, L., Wang, X., Yuan, K., Yin, T., Du, R., Shen, L., Zhu, Z., Yu, S., Zhang, H., & Wang, G. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.09.009 · Cited by 57
Personalised antiplatelet therapies for coronary artery disease: what the future holds
Capodanno, D., & Angiolillo, D. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad362 · Cited by 58
Bainey, K. R., Marquis‐Gravel, G., Belley‐Côté, E. P., Turgeon, R. D., Ackman, M. L., Babadagli, H. E., Bewick, D. J., Boivin‐Proulx, L., Cantor, W. J., Fremes, S. E., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.10.013 · Cited by 65
Novel aspects of antiplatelet therapy in cardiovascular disease
Gremmel, T., Michelson, A. D., Frelinger, A. L., & Bhatt, D. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12115 · Cited by 61
Li, Y., Wang, Y.-C., Wang, Y., Liu, J., Lee, C., Chen, C., Hsieh, C., Kuo, F. Y., Huang, W., Sung, S., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.06.002 · Cited by 59
Update on Cardiac Catheterization in Patients With Prior Coronary Artery Bypass Graft Surgery
Xenogiannis, I., Tajti, P., Hall, A. B., Alaswad, K., Rinfret, S., Nicholson, W. J., Karmpaliotis, D., Mashayekhi, K., Furkalo, S., Cavalcante, J. L., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.04.051 · Cited by 57
Carvalho, P. E. P., Gewehr, D. M., Nascimento, B. R., Melo, L., Burkhardt, G., Rivera, A., Braga, M. A. P., Guimarães, P. O., Mehran, R., Windecker, S., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3216 · Cited by 56
Schiele, F., Ecarnot, F., & Chopard, R. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317706586 · Cited by 60
Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Capranzano, P., & Angiolillo, D. J. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.040 · Cited by 60
Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction
Lee, S. H., Kim, H. K., Ahn, J., Kang, M. G., Kim, K., Bae, J. S., Cho, S. Y., Koh, J., Park, Y., Hwang, S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad088 · Cited by 55
Arima, Y., Kaikita, K., Ishii, M., Ito, M., Sueta, D., Oimatsu, Y., Sakamoto, K., Tsujita, K., Kojima, S., Nakagawa, K., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13256 · Cited by 60
Challenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616689773 · Cited by 59
Yoshikawa, Y., Shiomi, H., Watanabe, H., Natsuaki, M., Kondo, H., Tamura, T., Nakagawa, Y., Morimoto, T., & Kimura, T. (2017) · Circulation · doi:10.1161/circulationaha.117.028924 · Cited by 57
Rosselló, X., Bueno, H., Pocock, S., de Werf, F. V., Danchin, N., Annemans, L., Medina, J., & Zeymer, U. (2018) · Clinical Cardiology · doi:10.1002/clc.23116 · Cited by 55
Diabetes and antiplatelet therapy: from bench to bedside
Rios, J. R. R., Franchi, F., Rollini, F., & Angiolillo, D. J. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.05.09 · Cited by 59
Huo, Y., Jeong, Y., Gong, Y., Wang, D. W., He, B., Chen, J., Fu, G., Chen, Y., Li, J., Li, Y., et al. (2018) · 中国科学通报:英文版 · doi:10.1016/j.scib.2018.12.020 · Cited by 55
“The clinical outcomes from the DES-LATE [107] (n = 5,045: 100% from Korea) and DAPT [114] (n = 9,961: about 90% from North America) trials gave important insight regarding the benefit of prolonged DAPT (>30 vs.”
BackgroundDual Antiplatelet Therapy in Coronary Artery Disease
Sharma, R., Kumar, P., Prashanth, S. P., & Belagali, Y. R. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00197-0 · Cited by 58
Woods, L. T., Forti, K. M., Shanbhag, V., Camden, J. M., & Weisman, G. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114406 · Cited by 57
Proceedings From the Global Cardio-Oncology Summit
Lenihan, D. J., Fradley, M. G., Dent, S. F., Brezden‐Masley, C., Carver, J. R., Filho, R. K., Neilan, T. G., Blaes, A. H., Melloni, C., Herrmann, J., et al. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.007 · Cited by 56
Spencer, F. A., Prasad, M., Vandvik, P. O., Chetan, D., Zhou, Q., & Guyatt, G. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0083 · Cited by 52
Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds
Capodanno, D., & Angiolillo, D. J. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.12.279 · Cited by 52
“A large-scale randomized study showed that prolonging DAPT up to 30 months reduces significantly the risk of stent thrombosis, which is particularly true for firstgeneration DES (58).”
BackgroundCauses of late mortality with dual antiplatelet therapy after coronary stents
Mauri, L., Elmariah, S., Yeh, R. W., Cutlip, D. E., Steg, P. G., Windecker, S., Wiviott, S. D., Cohen, D. J., Massaro, J. M., D’Agostino, R. B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv614 · Cited by 52
Self-citationMeredith, I. T., Tanguay, J., Kereiakes, D. J., Cutlip, D. E., Yeh, R. W., Garratt, K. N., Lee, D. P., Steg, P. G., Weaver, W. D., Holmes, D. R., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.016783 · Cited by 52
Self-citation1-Year Results of the REMEDEE Registry
Woudstra, P., Kalkman, D. N., den Heijer, P., Menown, I. B. A., Ērglis, A., Suryapranata, H., Arkenbout, K., Íñiguez, A., Hof, A. W. J. V. ’., Müller, P. F., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.02.052 · Cited by 52
Bonaca, M. P., Goto, S., Bhatt, D. L., Steg, P. G., Storey, R. F., Cohen, M. C., Goodrich, E. L., Mauri, L., Ophuis, T. O., Ruda, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024637 · Cited by 54
Self-citationValgimigli, M., Landi, A., Angiolillo, D. J., Baber, U., Bhatt, D. L., Bonaca, M. P., Capodanno, D., Cohen, D. J., Gibson, C. M., James, S. K., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069012 · Cited by 53
Self-citationOno, M., Hara, H., Kawashima, H., Gao, C., Wang, R., Wykrzykowska, J. J., Piek, J. J., Garg, S., Hamm, C. W., Steg, P. G., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00870 · Cited by 53
Self-citationApixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes
Hess, C. N., James, S. K., Lópes, R. D., WOJDYLA, D. M., Neely, M. L., Liaw, D., Hagström, E., Bhatt, D. L., Husted, S., Goodman, S. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.027 · Cited by 51
“These results will have to be reconciled with those from the recent DAPT (Dual Antiplatelet Therapy) trial, which suggested benefit of prolonged dual antiplatelet therapy after PCI with a drug-eluting stent, and the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrel…”
ResultLemesle, G., Tricot, O., Meurice, T., Lallemant, R., Delomez, M., Equine, O., Lamblin, N., & Bauters, C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.050 · Cited by 50
Antithrombotic therapy for acute coronary syndrome: Past, present and future
Sibbing, D., Angiolillo, D. J., & Huber, K. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0963 · Cited by 52
“This recommendation is based on the results of the PEGASUS (47) and DAPT (63) trials, both of which evaluated the efficacy and safety of long-term (>12 months) DAPT treatment with either clopidogrel/prasugrel (DAPT) or ticagrelor (PEGASUS).”
BackgroundBiomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes
Batra, G., Lindbäck, J., Becker, R. C., Harrington, R. A., Held, C., James, S. K., Kempf, T., Lópes, R. D., Mahaffey, K. W., Steg, P. G., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.767 · Cited by 51
Self-citationPerfluorocarbons: A perspective of theranostic applications and challenges
Kakaei, N., Amirian, R., Azadi, M., Mohammadi, G., & Izadi, Z. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1115254 · Cited by 49
“Also, Thrombus formation is the prime concern for using blood-contacting medical devices (Mauri et al., 2007; Mauri et al., 2014; Grover and Mackman, 2019; Virani et al., 2020).”
BackgroundPercutaneous Coronary Revascularization
Serruys, P. W. J. C., Ono, M., Garg, S., Hara, H., Kawashima, H., Pompilio, G., Andreini, D., Holmes, D. R., Onuma, Y., & King, S. B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.024 · Cited by 50
Self-citationSecemsky, E. A., Matteau, A., Yeh, R. W., Steg, P. G., Camenzind, E., Wijns, W. C., McFadden, E. P., & Mauri, L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.03.010 · Cited by 48
Self-citationCurrent State of Bioabsorbable Polymer-Coated Drug-Eluting Stents
Hou, D., Huibregtse, B. A., Dawkins, K. D., Donnelly, J., Roy, K., Chen, J. P., & Akinapelli, A. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x12666161222155230 · Cited by 59
“(2014) demonstrated that a long-term (30-month) DAPT regimen resulted in significantly lower rates of thrombosis compared to a shorter (12-month) DAPT regimen, but was associated with a significantly increased risk of bleeding [20].”
BackgroundPredicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes
Alfredsson, J., Neely, B., Neely, M. L., Bhatt, D. L., Goodman, S. G., Tricoci, P., Mahaffey, K. W., Cornel, J. H., White, H. D., Fox, K. A. A., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-310090 · Cited by 50
Data Monitoring Committees: Current issues
Fleming, T. R., Ellenberg, S. S., & DeMets, D. L. (2018) · Clinical Trials · doi:10.1177/1740774518764855 · Cited by 48
“16 The DMC should have ongoing access to any available data needed to carry out their primary responsibilities.”
Choi, K. H., Song, Y. B., Lee, J. M., Park, T. K., Yang, J. H., Choi, J., Choi, S., Oh, J. H., Cho, D., Lee, J. B., et al. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008530 · Cited by 58
Valgimigli, M., Costa, F., Byrne, R. A., Haude, M., Baumbach, A., & Windecker, S. (2015) · EuroIntervention · doi:10.4244/eijv11i1a11 · Cited by 48
Vranckx, P., Leebeek, F. W. G., Tijssen, J. G. P., Koolen, J., Stammen, F., Herman, J.-P., de Winter, R. J., Hof, A. V. T., Backx, B., Lindeboom, W. K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0061 · Cited by 47
“This is despite the use of currently recommended 12-month antiplatelet therapy (i. e. DAPT), revascularisation procedures as appropriate, and other evidence-based secondary prevention measures (24–26) .”
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
Cherepanov, V., Cabrera-Fuentes, H. A., Kim, M. H., & Serebruany, V. L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0077 · Cited by 48
International patterns of dual antiplatelet therapy duration after acute coronary syndromes
Bueno, H., Pocock, S., Danchin, N., Annemans, L., Gregson, J., Medina, J., & de Werf, F. V. (2016) · Heart · doi:10.1136/heartjnl-2016-309509 · Cited by 47
9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System
Cutlip, D. E., Garratt, K. N., Novack, V., Barakat, M., Meraj, P., Maillard, L., Ērglis, A., Jauhar, R., Popma, J. J., Stoler, R., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.10.037 · Cited by 51
Self-citationSingle or dual antiplatelet therapy after PCI
Miyazaki, Y., Suwannasom, P., Sotomi, Y., Abdelghani, M., Tummala, K., Katagiri, Y., Asano, T., Tenekecioğlu, E., Zeng, Y., Cavalcante, R., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.12 · Cited by 49
Jang, W. J., Ahn, S. G., Song, Y. B., Choi, S., Chun, W. J., Oh, J. H., Cho, S. W., Kim, B. S., Yoon, J., Koo, B., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005849 · Cited by 47
Contemporary Management of Stable Coronary Artery Disease
Bertolone, D. T., Gallinoro, E., Esposito, G., Paolisso, P., Bermpeis, K., Colle, C. D., Fabbricatore, D., Mileva, N. B., Valeriano, C., Munhoz, D., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00497-z · Cited by 52
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“However, although prolonged DAPT improves the protection against ischaemic events in patients with high ischaemic risk, the approach also increases the risk of bleeding 131,132 , which necessitates individualized decision-making based on the thrombotic versus haemorrhagic risks 133 .”
Self-citationPasea, L., Chung, S., Pujades‐Rodríguez, M., Moayyeri, A., Denaxas, S., Fox, K. A. A., Wallentin, L. C., Pocock, S., Timmis, A., Banerjee, A., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw683 · Cited by 45
Uhrín, P., Wang, D., Mocan, A., Waltenberger, B., Breuss, J. M., Tewari, D., Mihaly‐Bison, J., Huminiecki, Ł., Starzyński, R. R., Tzvetkov, N. T., et al. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.002 · Cited by 45
Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome
Yin, D. R. P. P. C. P., Azzahhafi, J., & James, S. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093039 · Cited by 52
“The score was developed from the randomized DAPT study [53], in which PCI patients after 12 months DAPT were randomized to either aspirin with a P2Y12-inhibitor or to aspirin with placebo for an additional 18 months.”
MethodCosta, F., Adamo, M., Ariotti, S., Ferrante, G., Navarese, E. P., Leonardi, S., García‐García, H. M., Vranckx, P., & Valgimigli, M. (2016) · EuroIntervention · doi:10.4244/eijy15m08_04 · Cited by 44
First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent
Worthley, S. G., Abizaid, A., Kirtane, A. J., Simon, D. I., Windecker, S., Brar, S. K., Meredith, I. T., Shetty, S. V., Sinhal, A., Almonacid, A., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.10.020 · Cited by 44
Self-citationDuration of dual antiplatelet therapy in acute coronary syndrome
Wilson, S., Newby, D. E., Dawson, D. K., Irving, J., & Berry, C. (2017) · Heart · doi:10.1136/heartjnl-2016-309871 · Cited by 46
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
Giustino, G., Kirtane, A. J., Baber, U., Généreux, P., Witzenbichler, B., Neumann, F., Weisz, G., Maehara, A., Rinaldi, M., Metzger, C., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.034 · Cited by 43
Self-citationLindholm, D. P., Hagström, E., James, S. K., Becker, R. C., Cannon, C. P., Himmelmänn, A., Katus, H. A., Maurer, G., Lopez-Sendon, J. L., Steg, P. G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005580 · Cited by 44
Self-citationStratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
Ostrowska, M., Kubica, J., Adamski, P., Kubica, A., Eyileten, C., Postula, M. A., Toma, A., Hengstenberg, C., & Siller-Matula, J. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00176 · Cited by 45
Binder, R. K., & Lüscher, T. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv103 · Cited by 42
Secemsky, E. A., Yeh, R. W., Kereiakes, D. J., Cutlip, D. E., Steg, P. G., Massaro, J. M., Apruzzese, P. K., & Mauri, L. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.02.013 · Cited by 43
“The individual components of this endpoint were also reported to be consistent with the primary outcomes from the DAPT Study.”
BackgroundSelf-citation
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.